ESPR Q1 2023 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$24M+29.2% YoY

Gross Profit

$13M52.1% margin

Operating Income

-$49M-199.8% margin

Net Income

-$62M-253.7% margin

EPS (Diluted)

$-1.14

QoQ Revenue Growth

+29.3%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$54M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$252M

Total Liabilities

$581M

Stockholders' Equity

-$330M

Cash & Equivalents

$145M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24M	$19M	+29.2%
Gross Profit	$13M	$12M	+8.2%
Operating Income	-$49M	-$43M	-13.1%
Net Income	-$62M	-$57M	-8.8%

Revenue Segments

Product

$17M70%

Collaboration Revenue

$7M30%